Patents Issued in July 21, 2020
  • Compounds useful for treating cancer
    Patent number: 10717724
    Abstract: The present invention relates to a compound of formula (I): wherein A and A? independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: July 21, 2020
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Pierre Roux, Florence Mahuteau, Romain Najman, Gilles Gadea, Jamal Tazi, Didier Scherrer, Carsten Brock, Nathalie Cahuzac
  • Pyrrolidine GPR40 modulators
    Patent number: 10717725
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: July 21, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Elizabeth Anne Jurica, Zhenqiu Hong
  • Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors
    Patent number: 10717726
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: July 21, 2020
    Assignee: ORION CORPORATION
    Inventors: David Din Belle, Mikko Mäkelä, Mikko Passiniemi, Pekka Pietikäinen, Petteri Rummakko, Eija Tiainen, Matti Vaismaa, Gerd Wohlfahrt
  • Pyridinium compounds
    Patent number: 10717727
    Abstract: The present invention relates to novel pyridinium compounds, their isomers, steroisomers, atropisomers, conformers, tautomers, polymorphs, hydrates and solvates. The present invention also encompasses process for preparing novel compounds and pharmaceutical composition of said compounds. The invention further relates to the use of the above mentioned compounds for the preparation of medicament for use as pharmaceuticals.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: July 21, 2020
    Assignee: Torrent Pharmaceuticals Limited
    Inventors: Chaitanya Dutt, Rameshchandra Gupta, Manish Patel, Jaya Abraham, Vivek Mishra, Amit Kesarwani, Shailesh Deshpande, Shital Kumar Zambad, Anoop Mathur, Jignesh Kotecha, Sachin Latad, Anita Chaudhari
  • Potassium channel modulators
    Patent number: 10717728
    Abstract: Provided are compounds of the formula: and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: July 21, 2020
    Assignee: Cadent Therapeutics, Inc.
    Inventors: Dipak Vasantrao Amrutkar, Kelly Foster, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Janus Schreiber Larsen, Karin Sandager Nielsen
  • Thiamine-organic acid salt
    Patent number: 10717729
    Abstract: The present disclosure relates to novel thiamine-organic acid salt, and the method of making the novel thiamine-organic acid salt.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: July 21, 2020
    Assignee: Purdue Research Foundation
    Inventors: Lynne S Taylor, Lisa J Mauer, Vivekanand Bhardwaj
  • Dihydroisoquinoline compound
    Patent number: 10717730
    Abstract: Compositions containing the compound of general formula I: are disclosed. The compositions be used to prevent or treat hepatitis B virus infection.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: July 21, 2020
    Assignee: SUZHOU ARK BIOPHARMACEUTICAL CO., LTD.
    Inventors: Cheng Peng, Yang Zhou, Gang Zou, Danbin Li, Haiqing Yuan, Zhen Jim Wu, Xiashi Lv, Xiaogang Lai, Shaoyun Zhang
  • Nitrogen-containing aromatic heterocyclic compound
    Patent number: 10717731
    Abstract: A compound represented by general formula [I] wherein X represents N or the like, Y represents CH or the like; RA represents a cycloalkyl group which may be substituted or the like, R1 represents an alkyl group or the like, R2 represents an alkyl group which may be substituted or the like, R3 represents a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof has an inhibitory activity on aldosterone synthetase, and is useful as a prophylactic and/or therapeutic agent for various diseases or symptoms associated with aldosterone.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: July 21, 2020
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Ryo Sakakibara, Hideki Ushirogochi, Wataru Sasaki, Yuichi Onda, Minami Yamaguchi, Fumihiko Akahoshi
  • Inhibitors of influenza virus replication, application methods and uses thereof
    Patent number: 10717732
    Abstract: The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: July 21, 2020
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Qingyun Ren, Changhua Tang, Xiaohong Lin, Junjun Yin, Kai Yi
  • Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof
    Patent number: 10717733
    Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: July 21, 2020
    Assignee: Pharmaxis Ltd.
    Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
  • Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof
    Patent number: 10717734
    Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: July 21, 2020
    Assignee: Pharmaxis Ltd.
    Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
  • Solid forms of a compound for modulating kinases
    Patent number: 10717735
    Abstract: Forms of 4-(6-(3,5-dimethylisoxazol-4-yl)-1-[(1S)-1-(2-pyridyl)ethyl]pyrrolo[3,2-b]pyridin-3-yl)benzoic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the forms of Compound I.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: July 21, 2020
    Assignee: Plexxikon Inc.
    Inventors: Prabha N. Ibrahim, Hamid Rezaei, Marika Nespi, Ben Powell, Rashmin Patel
  • Pyrrole amides as alpha V integrin inhibitors
    Patent number: 10717736
    Abstract: The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: July 21, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guohua Zhao, James Mignone
  • Cyclopropylamines as LSD1 inhibitors
    Patent number: 10717737
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: July 21, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Chunhong He, Wenqing Yao, Fenglei Zhang
  • Pyrimidinone and its derivatives inhibiting factor XIa
    Patent number: 10717738
    Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: July 21, 2020
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Steve Courtney, Chris Yarnold, Stuart Flanagan, Gareth Brace, John Barker, Osamu Ichihara, Elise Gadouleau, Anthony Richardson, Takashi Kondo, Akira Imagawa, Shingo Nakatani, Ryo Suzuki, Sho Kouyama
  • Methods and compositions for inhibition of bromodomain-containing proteins
    Patent number: 10717739
    Abstract: The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: July 21, 2020
    Assignee: CONVERGENE LLC
    Inventors: Hariprasad Vankayalapati, Makoto Yoshioka, Jeffrey William Strovel, Janak Khimchand Padia
  • Solid forms of acalabrutinib and process for preparation thereof
    Patent number: 10717740
    Abstract: The present application relates to crystalline propylene glycol solvate of acalabrutinib and process for preparation thereof. The propylene glycol solvate of acalabrutinib may be selected from a group of racemic propylene glycol solvate, R-propylene glycol solvate and S-propylene glycol solvate of acalabrutinib. Specifically, the present application relates to crystalline forms RSV1, RSV2, RSV3 and RSV4 of acalabrutinib. Crystalline forms RSV2 and RSV3 are stable in all conditions and has excellent physico-chemical properties. The present application also relates to crystalline form RSVS of acalabrutinib.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: July 21, 2020
    Assignee: DR. REDDY'S LABORATORIES LIMITED.
    Inventors: Raja Sekhar Voguri, Vishweshwar Peddy
  • Cryptate compounds
    Patent number: 10717741
    Abstract: Disclosed herein is a method for coupling a first compound having the formula (I) with a second compound that contains a carbonyl group. Also disclosed herein are compounds that can be formed by this method, and uses for such compounds.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: July 21, 2020
    Assignees: Australian Nuclear Science and Technology Organisation, The Australian National University
    Inventors: Suzanne Virginia Smith, Eskender Mume, Gary James Perkins
  • Spiro[3H-indole-3,2?-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
    Patent number: 10717742
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: July 21, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Joachim Broeker, Nina Kerres, Christiane Kofink, Juergen Ramharter, Harald Weinstabl, Annika Gille, Stefan Goepper, Manuel Henry, Guenther Huchler
  • Intermediates and methods for the synthesis of halichondrin B analogs
    Patent number: 10717743
    Abstract: Methods of synthesizing intermediates useful for the synthesis of halichondrin B analogs are described.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: July 21, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Charles E. Chase, Atsushi Endo, Francis G. Fang, Jing Li
  • Compound for organic electric element, organic electric element comprising the same and electronic device thereof
    Patent number: 10717744
    Abstract: Provided are a compound represented by Formula 1, and an organic electric element comprising a first electrode, a second electrode, and an organic material layer formed between the first electrode and the second electrode, wherein the organic material layer comprised the compound represented by Formula 1, and the driving voltage of an organic electronic device can be lowered, and the luminous efficiency, color purity, and life span can be improved by comprising the compound represented by Formula 1 in the organic material layer.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: July 21, 2020
    Assignee: DUK SAN NEOLUX CO., LTD.
    Inventors: Junghwan Park, Jeongkeun Park, Hoyoung Jung, Moonsung Kang, Jong-jin Ha, Wonsam Kim, Seul-gi Kim, Munjae Lee
  • Inhibitors of Bruton's tyrosine kinase and method of their use
    Patent number: 10717745
    Abstract: The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: July 21, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Min Cai, Wei Chen, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Kevin D. Kreutter, Gang Li, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J. M. Wiener, Yao Wu, Kun Xiao, Feihuang Zhang, Yaoping Zhu
  • Chemical compounds
    Patent number: 10717746
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: July 21, 2020
    Assignee: ASTRAZENECA AB
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • Method for the manufacturing of 2-(3-(alkyl and alkenyl)morpholino)-ethan-1-ols
    Patent number: 10717747
    Abstract: The present invention relates to a method for the manufacture of 2-(3-(alkyl or alkenyl)morpholino)-ethan-1-ols by reduction of 8a-(alkyl and alkenyl)hexahydrooxazolo[2,3-c][1,4]oxazines encompassing a process for producing 2-(3-(4-propylheptyl)morpholino)ethan-1-ol with the INN name delmopinol. The invention also relates to 1-chloro-4-propylhept-3-ene, 1-iodo-4-propylhept-3-ene, 8a-(4-5 propylheptyl)hexahydrooxazolo[2,3-c][1,4]oxazine, 8a-(4-propylhept-3-en-1-yl)hexahydrooxazolo[2,3-c][1,4]oxazine and 2-(3-(4-propylhept-3-en-1-yl)morpholino)ethan-1-ol which are intermediates in the delmopinol process.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: July 21, 2020
    Assignee: Lundbeck Pharmaceuticals Italy S.P.A.
    Inventors: Carla De Faveri, Mariano Stivanello
  • 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
    Patent number: 10717748
    Abstract: The present invention provides a compound useful as an agent for the prophylaxis or treatment of neurodegenerative disease and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: July 21, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tatsuki Koike, Masato Yoshikawa, Haruhi Ando, William John Farnaby
  • Macrocyclic sulfondiimine compounds
    Patent number: 10717749
    Abstract: The present invention relates to novel macrocyclic sulfondiimine compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: July 21, 2020
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Jens Geisler, Daniel Hog, Arne Scholz, Kirstin Petersen, Philip Lienau, Christian Stegmann, Dorothee Andres, Kunzeng Zheng, Ping Gao, Gang Chen, Jiajun Xi, Simon Anthony Herbert, Gerhard Siemeister, Nicolas Werbeck
  • 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents
    Patent number: 10717750
    Abstract: PSMA-targeted PET/SPECT agents for imaging PSMA-positive cancer and or tumor neovasculature and PSMA-targeted radiotherapeutic agent for the treatment of PSMA-positive cancer or tumor neovasculature are disclosed. Methods of imaging PSMA expressing tumors, or cells and kits also are disclosed.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: July 21, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Ronnie C. Mease, Sangeeta Ray
  • Near-IR glucose sensors
    Patent number: 10717751
    Abstract: The present disclosure provides polymerizable luminescent dyes useful for incorporation into polymers. The dyes and the polymers can be used in sensing and imaging applications, for example, to provide accurate and optionally long term measurements of glucose in vivo. The present disclosure also provides sensors including the polymers described herein. The sensors can be implanted into a tissue of a subject and used for long-term or short-term continuous and semi-continuous collection of data of various biochemical analytes, optionally without the use of implantable hardware of any type and/or enzymatic and electrochemical detection methods.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: July 21, 2020
    Assignee: Profusa, Inc.
    Inventors: Soya Gamsey, Viachaslau Bernat, Alex Kutyavin, Jacob William Clary, Sulolit Pradhan
  • Dehydrogenative silylation, hydrosilylation and crosslinking using pyridinediimine cobalt carboxylate catalysts
    Patent number: 10717752
    Abstract: A process for producing a silylated product comprises reacting a mixture comprising (a) an unsaturated compound containing at least one unsaturated functional group, (b) a silyl hydride containing at least one silylhydride functional group, and (c) a catalyst, optionally in the presence of a solvent, to produce a dehydrogenative silylated product, a hydrosilylated product, or a combination of a dehydrogenative silylated product and a hydrosilylated product, wherein the catalyst is chosen from a pyridine diimine cobalt dicarboxylate complex or a cobalt carboxylate compound, and the process is conducted without pre-activating the catalyst via a reducing agent and/or without an initiator or promoter compound. The present catalysts have been found to be active in the presence of the silyl hydride employed in the silylation reaction.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: July 21, 2020
    Assignees: MOMENTIVE PERFORMANCE MATERIALS INC., PRINCETON UNIVERSITY
    Inventors: Paul Chirik, Christopher Schuster, Julie Boyer, Kenrick Lewis, Johannes G. P. Delis, Aroop K. Roy
  • Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof
    Patent number: 10717753
    Abstract: The present invention relates to the field of pharmaceutical chemistry, and relates to a deuterium-modified Brigatinib derivative, preparation method thereof, pharmaceutical composition containing the same and the uses of the deuterium-modified Brigatinib derivative and the pharmaceutical composition thereof in preparing a medicament for treating the disease mediated by anaplastic lymphoma kinase. The deuterium-modified Brigatinib derivative of the present invention has an excellent inhibitory activity on anaplastic lymphoma kinase and has better pharmacodynamic or pharmacokinetic properties relative to Brigatinib.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: July 21, 2020
    Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Inventors: Yinsheng Zhang, Baomin Liu, Beibei Yang
  • Metal complexes
    Patent number: 10717754
    Abstract: Metal complexes such as those of formula (I) are contemplated by the present invention. The metal complexes may be used in catalytic reactions as a catalyst. The catalytic reaction may be an autotransfer process, for example hydrogen borrowing. Improved catalytic activity has been observed with certain metal complexes of the invention.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: July 21, 2020
    Assignee: University of Leeds
    Inventors: Stephen Philip Marsden, Patrick Columba McGowan, Roberta Lanaro, Andrew John Blacker
  • Co-crystal forms of a novobiocin analog and proline
    Patent number: 10717755
    Abstract: Disclosed are co-crystal forms of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3?-fluoro-[1,1?-biphenyl]-2-yl)ethyl)-acetamide and L-proline or D-proline, their pharmaceutical compositions, processes of manufacture, and methods of use for treating neurodegenerative disorders such as diabetic peripheral neuropathy.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: July 21, 2020
    Assignee: Reata Pharmaceuticals, Inc.
    Inventors: Xin Jiang, John Allen Walling, Melanie J. Bevill, Christopher S. Seadeek, Jared P. Smit
  • Spinosyn derivatives as insecticides
    Patent number: 10717756
    Abstract: Compositions and methods for the production of derivatives of spinosyns are provided. The method produces spinosyn derivatives that exhibit activity towards insects, arachnids, and/or nematodes and are useful in the agricultural and animal health markets.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: July 21, 2020
    Assignee: AgriMetis, LLC
    Inventors: Andrew Calabrese, Brian Michael Green, David R. Spring, Jerome Yves Cassayre, Pasquale N. Confalone
  • Ketolides having antibacterial activity
    Patent number: 10717757
    Abstract: The present invention relates to ketolide compounds of Formula I. The compounds have good anti-microbial activities, reduced inhibition of cytochrome P4503A4 (CYP3A4), and acceptable safety of co-administration of other drugs. The present invention also relates to a pharmaceutical composition comprising compounds of Formula I and the method of treating anti-microbial infection by administering the compounds. Oral administration is a preferred route of administration.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: July 21, 2020
    Assignee: Biopharmati SA
    Inventors: Sergio Lociuro, Khalid Islam
  • D-amino acid compounds for liver disease
    Patent number: 10717758
    Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: July 21, 2020
    Assignee: IDENIX PHARMACEUTICALS LLC
    Inventors: Benjamin Alexander Mayes, Adel M. Moussa, Alistair James Stewart, David Dukhan
  • Non-enzymatic, salt-mediated synthesis of polynucleic acids
    Patent number: 10717759
    Abstract: Provided herein is a method for synthesizing polynucleic acids, comprising the steps of (a) providing an acidic solution substantially free of nucleic acid polymerase and lipids, but containing mononucleotides and a monovalent salt; (b) drying and resolubilizing the mixture of step (a) a plurality of times; and (c) recovering polynucleic acids from a resolubilized mixture of step (b). In certain aspects, the method further uses a low pH, e.g. about 3; it can utilize monophosphates, such as AMP rather than ATP; and it can be used with a polynucleotide template to form a sequence at least partially complementary to said template. Thus, both single-stranded and double-stranded polynucleic acids are provided. Ammonia salts have been used to obtain RNA lengths from 10 to 300 nucleotides after 16 half hour cycles and an effective temperature includes between 80° C. and 100° C.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: July 21, 2020
    Assignees: The Regents of the University of California, Sorbonne Universite
    Inventors: David W. Deamer, Marie-Christine Maurel, Laura Da Silva
  • Therapeutically active steroidal derivatives
    Patent number: 10717761
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: July 21, 2020
    Assignee: FORENDO PHARMA LTD
    Inventors: Leena Hirvelä, Marjo Hakola, Tero Linnanen, Pasi Koskimies, Camilla Stjernschantz
  • Abiraterone derivative and formulations thereof
    Patent number: 10717762
    Abstract: This document relates to an abiraterone derivative, 2-(((3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-2-oxoacetic acid (ABOA). This document also relates to compositions comprising a non-covalently bound complex comprising ABOA and human serum albumin, wherein the ABOA and the human serum albumin in the composition have a ratio of weight from about 1:1 to about 1:2000. This document also relates to compositions comprising ABOA and human serum albumin, wherein the ABOA and the human serum albumin in the composition have a ratio of weight from about 1:1 to about 1:2000. This document also relates to compositions consisting essentially of ABOA and human serum albumin, wherein the ABOA and the human serum albumin in the composition have a ratio of weight from about 1:1 to about 1:2000.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: July 21, 2020
    Inventor: Qun Sun
  • Compositions containing HC-HA/PTX3 complexes and methods of use thereof
    Patent number: 10717763
    Abstract: Provided herein are methods for the production of native and reconstituted hyaluronan (HA) complexes containing pentraxin-3 (PTX3) and heavy chain 1 (HC1) of inter alpha inhibitor (I?I). Compositions containing the complexes and therapeutic methods using the complexes are provided. Combinations and kits for use in practicing the methods also are provided.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 21, 2020
    Assignee: TISSUETECH, INC.
    Inventors: Scheffer Tseng, Hua He, Sean Tighe, Suzhen Zhang, Ying-Tieng Zhu
  • Therapeutically active compounds and their methods of use
    Patent number: 10717764
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: July 21, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Janeta Popovici-Muller, Rene M. Lemieux, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
  • Compositions and methods for treating autoimmune and inflammatory disorders
    Patent number: 10717765
    Abstract: Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: July 21, 2020
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Carl Ware, John Sedy
  • Antimicrobial peptides and uses thereof
    Patent number: 10717766
    Abstract: A fragment of a virulent peptide named phenol-soluble modulin (PSM) having anti-bacterial activity and methods for eliminating bacteria are provided.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: July 21, 2020
    Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
    Inventors: Meytal Landau, Asher Moshe, Nir Salinas
  • Bioactive polypeptides for improvements in plant protection, growth and productivity
    Patent number: 10717767
    Abstract: Bioactive priming polypeptides are provided that are useful when applied to plants in agricultural formulations. Methods of using the formulations containing the bioactive priming polypeptides are also provided which are applied exogenously to the surface of a plant or a plant cell membrane or endogenously to the interior of a plant or to a plant cell. The bioactive priming polypeptides when applied to a plant, a plant part, or a plant growth medium or a rhizosphere in an area surrounding the plant or the plant part increase growth, yield, health, longevity, productivity, and/or vigor of a plant or a plant part and/or decrease abiotic stress in the plant or the plant part and/or protect the plant or the plant part from disease, insects and/or nematodes, and/or increase the innate immune response of the plant or the plant part and/or change plant architecture.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: July 21, 2020
    Assignee: Spogen Biotech, Inc.
    Inventors: Brian Thompson, Michelle Leslie
  • Proteins from anaerobic fungi and uses thereof
    Patent number: 10717768
    Abstract: Provided herein are novel proteins and protein domains from newly discovered anaerobic fungal species. The anaerobic fungal species have unique enzymatic capabilities, including the ability to digest diverse lignocellulosic biomass feedstocks and to synthesize secondary metabolites. The scope of the invention encompasses novel engineered proteins comprising glycoside hydrolase enzymes, dockerin domains, carbohydrate binding domains, and polyketide synthase enzymes. The invention further encompasses artificial cellulosomes comprising novel proteins and domains of the invention. The scope of the invention further includes novel nucleic acid sequences coding for the engineered proteins of the invention, and methods of using such engineered organisms to degrade lignocellulosic biomass and to create polyketides.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: July 21, 2020
    Assignee: The Regents of the University of California
    Inventors: Michelle O'Malley, Kevin Solomon, Charles Haitjema
  • Channelrhodopsins for optical control of cells
    Patent number: 10717769
    Abstract: The invention, in some aspects relates to compositions and methods for altering cell activity and function and the introduction and use of light-activated ion channels.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: July 21, 2020
    Assignees: Massachusetts Institute of Technology, The Governors of the University of Alberta
    Inventors: Nathan Klapoetke, Brian Yichiun Chow, Edward Boyden, Gane KA-Shu Wong, Yongku Peter Cho
  • Compositions and methods for increasing plant growth and yield using rice promoters
    Patent number: 10717770
    Abstract: Compositions and methods for improving plant growth are provided herein. Compositions comprise promoter sequences that direct expression of an operably linked nucleotide in a developmentally regulated manner. Polynucleotides, polypeptides, and expression constructs for expressing genes of interest whose expression may improve agronomic properties including but not limited to crop yield, biotic and abiotic stress tolerance, and early vigor, plants comprising the polynucleotides, polypeptides, and expression constructs, and methods of producing transgenic plants are also provided.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: July 21, 2020
    Assignee: Benson Hill, Inc.
    Inventors: Thomas P. Brutnell, Douglas W. Bryant, Todd Christopher Mockler, Lin Wang
  • Treatment of ischemia
    Patent number: 10717771
    Abstract: A system, including methods and compositions, for treatment of ischemia.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: July 21, 2020
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Roger P. Simon, Zhi-Gang Xiong
  • Recombinant binding proteins targeting HER2 and serum albumin, and their uses
    Patent number: 10717772
    Abstract: New recombinant binding proteins, comprising designed ankyrin repeat domain(s) with binding specificity for HER2, and comprising designed ankyrin repeat domain(s) with binding specificity for serum albumin, are disclosed, as well as nucleic acids encoding such recombinant binding proteins, pharmaceutical compositions comprising such recombinant binding proteins or nucleic acids and the use of such recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: July 21, 2020
    Assignee: Molecular Partners AG
    Inventors: Clara Metz, Ulrike Fiedler, Ignacio Dolado, Heike Maria Strobel
  • Polypeptide tagging fusions and methods
    Patent number: 10717773
    Abstract: This disclosure describes fusion polypeptides and complexes, compositions, and methods involving the fusion polypeptides. Generally, the fusion polypeptides include at least a portion of a protein of interest and at least a functional portion of a HUH polypeptide. Generally, the functional portion of a HUH polypeptide includes at least a portion of a Rep/relaxase domain that includes at least one catalytic polar amino acid residue and at least one metal-coordinating amino acid residues.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: July 21, 2020
    Assignee: Regents of the University of Minnesota
    Inventors: Wendy Ryan Gordon, Klaus Norman Lovendahl
  • Compositions and methods for treating cancers
    Patent number: 10717774
    Abstract: Compositions and methods for treating solid and hematological cancers, including Acute Myeloid Leukemia (AML), are provided herein. The methods include administering truncated, dominant-negative, forms of Galectin-3.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: July 21, 2020
    Assignee: KIROMIC, INC.
    Inventors: Maurizio Chiriva-Internati, Leonardo Mirandola